

**RADIANT.00.Data Collection Summary  
Rare and Atypical DIAbetes NeTwork  
Summary of Completed Study Forms  
Data Current as of May 2, 2024**

Form Name	# Completed Forms*
RADIANT Screening Questionnaire: Diabetes Diagnosis & Other Conditions, Referral to RADIANT	1,690
RADIANT Stage 1 Questionnaire: Demographics, Current Diabetes Status and Treatment, Patient and Family History	1,278
Treating Physician Questionnaire	261
Detailed Family History	395
Stage 3 Visit Eligibility Checklist	338
Vitals	337
Anthropometrics	325
Photography	323
Coordinator Physical Exam	324
Investigator Physical Exam	320
Acanthosis	319
Hirsutism	167
Tanner Staging	10
Michigan Neuropathy Screening Instrument (MNSI) Self Assessment	323
Michigan Neuropathy Screening Instrument (MNSI) Physical Assessment	323
Physical Functioning	324
Mini-Mental State Examination (MMSE2)	302
PROMIS Global General Health Item	293
PROMIS Global Mental Health Item	292
PROMIS Physical Health Item	293
PROMIS Global Social Activities Roles Item	293
PROMIS Cognitive Function Parent/Proxy Questionnaire	18
PROMIS Cognitive Function Pediatric Questionnaire	17
PROMIS Cognitive Function 8a	291
PROMIS Global Health Parent/Proxy Questionnaire - Fatigue	18

**\*Forms with 'complete' status, i.e. required responses have been entered.**

**RADIANT.00.Data Collection Summary  
Rare and Atypical DIAbetes NeTwork  
Summary of Completed Study Forms  
Data Current as of May 2, 2024**

Form Name	# Completed Forms*
PROMIS Global Health Parent/Proxy Questionnaire - Pain	18
PROMIS Global Health Parent/Proxy Questionnaire	18
PROMIS Global Health Pediatric Questionnaire - Fatigue	17
PROMIS Global Health Pediatric Questionnaire - Pain	17
PROMIS Global Health Pediatric Questionnaire	17
Education Questionnaire	314
Environmental Exposure Questionnaire	308
Medication Inventory	322
Oral Glucose Tolerance Test (OGTT)	327
Physical Activity Questionnaire (PAQ)	324
Stage 3 Standard Visit Specimen Collection	332
ASA24 Food Recall Questionnaire	174
	11,062

**\*Forms with 'complete' status, i.e. required responses have been entered.**

**RADIANT.00.Data Collection Summary**  
**Rare and Atypical DIAbetes NeTwork**  
**Summary of Samples Provided by RADIANT Participants**  
**Data Current as of May 2, 2024**

<b>Participants Providing Samples for:</b>	<b>Sample Type Test</b>	<b># of Participants Providing Samples</b>	<b># of Samples Received</b>
Stage 1 Autoantibody Testing	Serum for BAA	966	6,566
Stage 2 Genetic Testing	DNA Extraction (WGS)	427	2,882
	RNA Extraction (RNA-Seq)	426	1,230
Stage 2 Unaffected Family Member Testing	Fasting Glucose	36	37
Stage 2 Family Member Genetic Testing	DNA Extraction (Sanger)	52	256
	DNA Extraction (WGS Trio)	3	15
Stage 3 Standard Visit Testing	Serum for Storage, CMP, Lipid Profile	319	3,887
	Plasma for Storage, Metabolomics	325	5,931
	Plasma for OGTT glucose at -10, 0, 15, 30, 60, 90, 120 minutes	324	2,150
	Plasma for OGTT c-peptide and insulin at -10, 0, 15, 30, 60, 90, 120 minutes	324	9,637
	Urine (fasting)	324	3,228
	HbA1c	362	365
	PBMC	164	728
			36,912

**RADIANT.00.Data Collection Summary**  
**Rare and Atypical DIABetes NeTwork**  
**Summary of Stage 3 Samples by RADIANT Participant Clinical Category**  
**Data Current as of May 2, 2024**

Clinical Category*	Cases	Serum Samples for Storage, CMP, Lipid Profile	Plasma Samples for Storage, Metabolomics	Plasma Samples for OGTT Glucose**	Plasma Samples for OGTT C-peptide & Insulin**	Urine Samples	HbA1c Samples	PBMC Samples	Total Samples
All Cases Reviewed by the Discovery Team	210	2,440	3,805	1,396	6,144	2,078	210	659	16,732
Non-obese insulin insufficient DM	94	1,084	1,701	638	2,806	928	94	276	7,527
Possible monogenic or oligogenic	65	739	1,155	438	1,865	628	66	237	5,128
Antibody negative, insulin deficient diabetes	51	604	929	332	1,409	510	52	173	4,009
Syndromic	30	340	552	186	855	290	31	109	2,363
Other	25	283	460	165	718	250	24	96	1,996
Lipodystrophic	22	231	377	153	648	220	23	81	1,733
A-B+ ketosis prone diabetes	17	222	324	119	586	170	17	79	1,517
Non-progressive	15	163	267	95	432	150	15	47	1,169
Very low insulin requirements	13	154	245	85	371	130	13	49	1,047
Severe insulin resistance	12	135	215	83	374	120	12	45	984
Lean GDM	9	93	170	60	234	81	9	22	669
Mitochondrial	9	114	172	52	248	90	9	33	718
A-B- ketosis prone diabetes	8	89	136	49	211	80	8	27	600
Molecular Mechanisms of Beta Cell Dysfunction	8	88	139	44	186	80	8	24	569
Lean PCOS	5	61	98	35	160	50	5	16	425
Diabetes associated with congenital or inherited pancreatic disease	4	50	73	22	106	30	4	15	300
IRS2 Haploinsufficiency variant	4	36	77	28	126	40	4	18	329
INSR variant	3	40	57	21	105	30	3	7	263
INS variant	3	35	71	28	108	30	3	5	280
IGF1R variant	2	23	36	14	56	20	2	15	166
SLIT2-ROBO1 variant	2	14	31	14	45	20	2	5	131

\*Clinical categories are assigned by the RADIANT Discovery Team after the Stage 3 visit. A participant can be assigned to more than one Clinical Category by the Discovery Team.

\*\*Total for all time points. Samples are obtained to measure glucose/c-peptide/insulin at -10, 0, 15, 30, 60, 90, 120 minutes.

**RADIANT.00.Data Collection Summary**  
**Rare and Atypical DIAbetes NeTwork**  
**Summary of Stage 3 Samples by RADIANT Participant Clinical Category**  
**Data Current as of May 2, 2024**

Clinical Category*	Cases	Serum Samples for Storage, CMP, Lipid Profile	Plasma Samples for Storage, Metabolomics	Plasma Samples for OGTT Glucose**	Plasma Samples for OGTT C-peptide & Insulin**	Urine Samples	HbA1c Samples	PBMC Samples	Total Samples
mTor Pathway	2	30	40	14	70	20	2	6	182
CERS2 variant	1	14	19	7	35	10	1	4	90
EIF2S1 variant	1	10	20	7	35	10	1	13	96
GLUT4 variant	1	9	19	7	29	10	1	0	75
IDH2 variant	1	10	18	6	20	10	1	1	66
LMNTD2 variant	1	12	20	7	33	10	1	1	84
NFKB1 variant	1	15	20	7	35	10	1	6	94
PAX6 variant	1	15	20	7	35	10	1	5	93
PTPMT1 variant	1	11	16	7	31	10	1	2	78
Pre-pubertal T2D	1	4	17	6	21	10	1	3	62
SMAD5 variant	1	12	20	7	35	10	1	5	90
Fulminant	0	0	0	0	0	0	0	0	0

\*Clinical categories are assigned by the RADIANT Discovery Team after the Stage 3 visit. A participant can be assigned to more than one Clinical Category by the Discovery Team.

\*\*Total for all time points. Samples are obtained to measure glucose/c-peptide/insulin at -10, 0, 15, 30, 60, 90, 120 minutes.